BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Podentamig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Podentamig\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04184050-3415@assetmemo.bio
DTSTAMP:20261121T005442Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Podentamig: Phase 1 readout est. (NCT04184050)
DESCRIPTION:Podentamig\, phase 1\, Multiple Myeloma.\nStudy: Study of HPN21
 7 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-40
 02-001)\nEstimated primary completion: 31 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/podentamig#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04184050
URL:https://assetmemo.bio/drug/podentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
